Compare Novo Nordisk A/S (NVO) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Novo Nordisk A/S trades at $46.32 (market cap $207.85B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.31. The key difference: Novo Nordisk A/S pays a 3.81% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and Novo Nordisk A/S is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| NVO | YMAG | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $63.98 | $15.98 |
52-Week Low | $35.29 | $10.76 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
YMAG trades at $11.29, down 2.59% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividends, with recent payouts ranging from $0.07 to $0.40, highlighting its income-focused strategy. News coverage emphasizes distribution announcements and NAV stability concerns amid earnings volatility.
Outlook hinges on sustained option income generation, but risks include NAV decay from call spreads and market volatility. Analyst sentiment is mixed, with some viewing it as a tactical buy in rangebound markets. Key risks are earnings-driven NAV swings and competitive ETF structures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
